The goal of this project is to engage more families of children with CHD8 mutations with a novel online platform (GroopIt) and to empower families to be partners in research. We are utilizing a community-based participatory research (CBPR) approach to enable families to identify research priorities. Through an established Facebook group for CHD8, families will […]
Prazosin, a drug that prevents the neurotransmitter norepinephrine from binding to its alpha1 receptor (alpha1-AR) subtype has shown efficacy in reducing PTSD symptoms in most, but not all, studies of trauma-exposed Service Members, Veterans, and civilians. However, it is not effective in all patients and its use is complicated by variability in effective doses, a […]
The proposed research will be a preliminary investigation into the potential association between microbiota abundance, hormone levels, peripheral inflammation and current symptoms (psychiatric and cognitive) in Veterans with and without a history of mild traumatic brain injury (mTBI). This work has the potential to form a new line of research that could ultimately provide new […]
Project SARAH is a randomized clinical trial providing treatment for PTSD and alcohol use in the first year following sexual assault for individuals who identify as female. The study aims to test 1) the role of fear and reward in recovery following sexual assault; 2) the efficacy of a PTSD vs an alcohol intervention for […]
This developmental project examines the feasibility, acceptability, and preliminary impact of Volunteer-delivered Behavioral Activation (BA), in comparison to MSW-delivered BA, among depressed senior center clients.
The GENDAAR 2.0 study is part of the Autism Center of Excellence (ACE Network), which includes researchers from across the country. The main goal of this follow up study is to investigate the transition through adolescence and into young adulthood. We aim to identify sex differences in individuals with autism spectrum disorders (ASD) and look […]
To evaluate the efficacy of ZYN002 administered as a transdermal gel formulation, for up to 12 weeks, in patients ages 3 to <18 years, in the treatment of symptoms of Fragile X Syndrome (FXS).
To examine the safety, tolerability, and efficacy of arbaclofen for the treatment of neurodevelopmental impairments in subjects with 16p11.2 deletion
This is a multicenter longitudinal study that aims to identify, develop and validate a set of measures that can be used as stratification biomarkers and/or sensitive and reliable objective measures of social impairment in ASD that could serve as markers of long term clinical outcome.